Can Hydroxychloroquine Cause Hepatic Dysfunction?
Yes, hydroxychloroquine can cause hepatic dysfunction, though it is considered a rare but potentially serious adverse effect. The NIH LiverTox resource rates hydroxychloroquine with a likelihood score of D (possible rare cause of clinically apparent liver injury) 1.
Hepatotoxicity Profile
Hydroxychloroquine is rarely linked to aminotransferase elevations or clinically apparent liver injury in the general population 1. However, the drug is known to concentrate in the liver, making certain patient populations particularly vulnerable 1.
High-Risk Populations Requiring Caution
Exercise extreme caution or avoid hydroxychloroquine entirely in patients with:
- Porphyria cutanea tarda (PCT) or acute intermittent porphyria - Can trigger hypersensitivity attacks with fever, marked serum aminotransferase elevations (>20 times upper limit of normal), and jaundice, sometimes resulting in fulminant hepatic failure 1, 2, 3
- Pre-existing hepatitis or other hepatic diseases 1
- Concurrent use of other hepatotoxic drugs 1
- Alcohol use - even if discontinued during treatment 4
The FDA drug label specifically warns about hepatotoxicity in PCT patients, noting that cases have presented with marked transaminase elevations within days to a month of initiation, with some patients requiring liver injury workup before PCT was even diagnosed 2.
Clinical Presentation and Timing
When hepatotoxicity occurs, it typically manifests as:
- Elevated AST and ALT (can be >10-fold increase) 5, 6, 7
- Hyperbilirubinemia 4
- Symptoms: fatigue, nausea, dark urine, jaundice 2
- Onset: Usually within 2 weeks to 1 month of starting therapy 8
Severe cases can progress to fulminant hepatic failure, as documented in case reports where patients developed liver failure within two weeks of starting hydroxychloroquine, with one requiring emergency liver transplantation and another dying before transplant 8.
Monitoring Recommendations
For patients on hydroxychloroquine therapy:
- Measure baseline liver function tests before initiating therapy 1
- Monitor LFTs throughout treatment, particularly in the first month 1, 4
- Promptly measure liver tests in patients reporting symptoms suggestive of liver injury 2
Discontinue hydroxychloroquine immediately if:
- ALT >3 times upper limit of normal with symptoms
- Total bilirubin >2 times upper limit of normal
- Any clinical signs of hepatotoxicity 2
Recovery Pattern
The hepatotoxicity is generally reversible upon drug discontinuation. In documented cases, liver enzymes typically down-trend within days and return to baseline within 2 months after stopping hydroxychloroquine 5, 6, 7. However, this requires prompt recognition and cessation of the drug.
Special Considerations
The risk-benefit assessment is critical: While hepatotoxicity is rare, it can be life-threatening. The drug should never be offered to patients with the high-risk factors listed above 4. In COVID-19 treatment contexts, guidelines noted that abnormal liver function tests are not an absolute contraindication to hydroxychloroquine use, but this reflects the emergency use authorization context rather than routine clinical practice 4.
Important caveat: It can be difficult to distinguish whether liver dysfunction is due to hydroxychloroquine itself, the underlying disease process (e.g., lupus hepatitis), disease complications, or other concurrent medications 4. This makes careful monitoring and a high index of suspicion essential.